TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

TRACON Pharmaceuticals (TCON) announced that CEO Charles Theuer will present at three investor conferences in September 2022. Key events include the Wells Fargo 2022 Healthcare Conference on September 9 at 9:10 AM EDT, and the H.C. Wainwright and RW Baird conferences on September 14 at 3:00 PM and 11:25 AM EDT, respectively. TRACON is focusing on advancing its cancer therapeutics pipeline, which includes Envafolimab and YH001, and is seeking partnerships to enhance its product development capabilities.

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview:

• Wells Fargo 2022 Healthcare Conference – September 9^th at 9:10am EDT
• H.C. Wainwright 24^th Annual Global Investment Conference – September 14^th at 3:00pm EDT
• RW Baird 2022 Global Healthcare Conference – September 14^th at 11:25am EDT
  

To access a live webcast or replay of the Wells Fargo and H.C. Wainwright conference presentations, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.

About TRACON

TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent.   To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

Company Contact:	Investor Contact:
Mark Wiggins	Brian Ritchie
Chief Business Officer	LifeSci Advisors LLC
(858) 251-3492	(212) 915-2578
mwiggins@traconpharma.com	britchie@lifesciadvisors.com

FAQ

When will TRACON Pharmaceuticals present at the Wells Fargo 2022 Healthcare Conference?

TRACON Pharmaceuticals will present at the Wells Fargo 2022 Healthcare Conference on September 9, 2022, at 9:10 AM EDT.

What are the dates for TRACON Pharmaceuticals at the H.C. Wainwright conference?

TRACON Pharmaceuticals will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 3:00 PM EDT.

What is the timing for TRACON at the RW Baird Global Healthcare Conference?

TRACON will participate in the RW Baird 2022 Global Healthcare Conference on September 14, 2022, at 11:25 AM EDT.

What is TRACON Pharmaceuticals' focus in drug development?

TRACON Pharmaceuticals focuses on developing novel targeted cancer therapeutics and seeks partnerships to enhance its product development.

Where can I access TRACON Pharmaceuticals' conference presentations?

You can access live webcasts or replays of TRACON Pharmaceuticals' presentations by visiting the 'Events and Presentations' page on their website.